( PRINCETON N.J.--(BUSINESS WIRE)--May 2...)Cytogen Reports Publication Validating the Utility of its,Proprietary ProChart Database,Health

PRINCETON, N.J.--(BUSINESS WIRE)--May 23, 2007 - Cytogen Corporation (NASDAQ: CYTO) today reported the publication of a review validating the utility of its ProChart(TM) database to help define the function of the WW domain-containing oxidoreductase (WWOX), an important tumor suppressor gene with known involvement in breast, prostate, lung, pancreatic, esophageal, and gastric cancers. The peer-reviewed article was published in the online edition (25 April 2007) of the Journal of Cellular Physiology as a Mini Review entitled "WWOX in biological control and tumorigenesis," by Rami I. Aqeilan and Carlo M. Croce, epub 25 April 2007. The publication focuses on the most recent progress in understanding the function of WWOX as a tumor suppressor.

WW and other modular domain families are known to be important in mediating many important protein-protein interactions. Because WWOX contains two WW domains, it was an ideal protein to analyze with ProChart, Cytogen's proprietary, comprehensive, experimentally validated database of protein-protein signaling interactions. Using ProChart, the authors were able to determine a number of novel WWOX-interacting proteins, including the transcription factors p73 and Ap-2 gamma, the latter of which is known to play a role in activating the expression of the epidermal growth factor, HER2 (erbB-2). The study also reviews the importance of the relationships between WWOX and critical proto-oncogenes such as ErbB4 and c-Jun.

Using ProChart to accelerate their studies of WWOX, in recent years researchers from Ohio State University have validated a number of key WWOX interactions and published several peer-reviewed journal articles. Prior to the application of ProChart, little was known about the specific biologic functions of WWOX protein expression or the signaling pathways that lead to its tumor suppressive effects. In the current publication, the authors specifically refer to the
'"/>

Page: 1 2 3 4
Related medicine technology :

1. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
2. Vion Pharmaceuticals Presents Clinical Data from a Phase II Trial of Cloretazine (VNP40101M) in Elderly AML Patients with Unfavorable Cytogenetics at EHA Meeting
3. New Data for Cytogens QUADRAMET Reported at Annual ASCO Meeting
4. Preclinical Data on Cytogens Technology to be Reported at the AACR Annual Meeting
5. New Clinical Data for Cytogens Quadramet and Prostacint to be Reported at Upcoming Major Medical Meetings
6. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
7. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
10. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
11. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece